ENTITY

CSL (CSL AT)

2
Analysis
Health Care • United States
CSL Limited develops, manufactures, and markets human pharmaceutical and diagnostic products derived from human plasma. The Company provides products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.
more
•29 Aug 2019 12:37

ASX Reporting Season Update: Misses and Downgrades Amongst Bright Spots

Reporting season has been relatively disappointing with only 45% of stocks able to either meet or beat FY19 expectations. Analyst expectations in...

Logo
723 Views
Share
bullish•MSCI ACWI Index
•21 Jun 2019 06:57

Global Equities Nearing Potential Resistance

we believe global equities remain in a state of purgatory and consolidation is likely to continue as several major indexes approach logical...

Logo
627 Views
Share
•28 May 2019 12:01

Time to Dissect Aussie Growth Stocks

Growth stocks have again out-performed Value since the start of the year supported by declining bond yields and solid EPS growth. In our March...

Logo
754 Views
Share
•01 Jun 2026 10:26

MS-Australia Index Earning Revision (May): Evolution Mining, National Australia Bank, CSL, ANZ

We analyzed MS-Australia's consensus for May 2026 and highlighted changes of EPS in Evolution Mining, National Australia Bank, CSL, ANZ, Brambles,...

Logo
127 Views
Share
•06 Mar 2019 06:07

Aussie Equities Reporting Season Wrap: March 2019

Australia rallied strongly through a relatively solid reporting season, with the benchmark ASX 200 posting a strong 6% gain in the month. EPS was...

Logo
385 Views
Share
x